New Study Heralds Shortened Timeline for Anticancer Drug Development
Source: NIH News
A new compound, called ABT-888, has passed the first stage of clinical examination using a new model for drug development that promises to shorten — by up to six to 12 months — the timeline for taking anticancer drugs from the laboratory to the clinic, according to a team of researchers at the National Cancer Institute (NCI), part of the National Institutes of Health. This result (abstract #3518) was presented June 3, 2007, at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill.
External Link: http://www.nih.gov/news/pr/jun2007/nci-03.htm